IBI-10090

13452978_s


The lead pipeline product using the Verisome® technology is IBI-10090 which is being developed as a biodegradable therapeutic for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.

IBI-10090 will be Icon’s first product developed using the Verisome® technology to reach the market.  IBI-10090 is a biodegradable product for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.

IBI-10090 is intended to be injected into the anterior chamber of the eye immediately after cataract surgery and safely deliver therapeutic levels of the active ingredient, dexamethasone.

A Phase 3 trial is currently enrolling patients. More information can be found on clinicaltrials.gov.

Share
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049
Copyright © 2014 Icon Bioscience, Inc. · Optimization by MME ·